GlassScriptPhysician profile
Drew W Dula
NPI 1386050821
$13,290.87
in general payments reported to CMS, 2019-2025
56 companies · $1,767 in 2025
The $1,767 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,586 · 2020: $1,255 · 2021: $2,228 · 2022: $2,136 · 2023: $1,484 · 2024: $1,835 · 2025: $1,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,085.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,183.34 | 2019-2025 | Qulipta, Ubrelvy, Duopa |
| Teva Pharmaceuticals USA, INC. | $853.89 | 2019-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $758.29 | 2019-2025 | Briviact, Zilbrysq, Rystiggo |
| Novartis Pharmaceuticals Corporation | $651.96 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $647.31 | 2019-2024 | Ultomiris, Soliris |
| Biogen, INC. | $611.55 | 2019-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $562.15 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Neurocrine Biosciences, INC. | $558.74 | 2020-2025 | Ingrezza, Ongentys |
| Biohaven Pharmaceuticals, INC. | $464.09 | 2021 | |
| Supernus Pharmaceuticals, INC. | $451.74 | 2019-2022 | |
| Amgen INC. | $434.86 | 2019-2024 | Aimovig |
| Acadia Pharmaceuticals INC | $431.21 | 2019-2025 | Nuplazid |
| Sk Life Science, INC. | $353.55 | 2020-2025 | |
| Eisai INC. | $349.42 | 2019-2025 | |
| Allergan, INC. | $258.60 | 2019-2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Dula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.